Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-281: capivasertib + abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer
2023-504998-20-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in prostate adenocarcinoma and prostate cancer (PCa) comparing Capivasertib + abiraterone with Placebo + abiraterone (2 arms). Primary endpoint: Radiographic progression-free survival. Planned start Sep 2020; status: authorised.
02
Drugs
capivasertibabiraterone
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on 2023-504998-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504998-20-00.